Watson Biotechnology

Walvax Biotechnology is a leading Chinese biopharmaceutical company specializing in the research, development, manufacturing, and distribution of human vaccines. Founded in 2001 and headquartered in Kunming, the company has established four major technology platforms: polysaccharide and conjugate vaccines, recombinant protein and VLP vaccines, mRNA vaccines, and adenovirus vector vaccines. Its commercial portfolio includes blockbuster products such as the 13-valent pneumococcal conjugate vaccine (PCV13) and the bivalent HPV vaccine. Walvax is notably a pioneer in mRNA technology in China, having developed the first domestic mRNA COVID-19 vaccine (AWcorna) in collaboration with Abogen Biosciences. The company is actively expanding its global footprint through partnerships and local production agreements in emerging markets like Malaysia, Indonesia, and Egypt.